Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Avertto logo — Monitor. Detect. Alert

Avertto

Monitor. Detect. Alert

Founded 2019 Israel Israel 10 employees Pre-Seed Total: $75.00K Health Care

General Information

Company Name Avertto
Founded Year 2019
Location Israel Israel
Employees 10
Industries Health Care
Funding Stage Pre-Seed
Social

BounceWatch is an independent company data service, not affiliated with Avertto. To contact Avertto, visit Avertto.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Avertto compare?

A PDF of Avertto and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Avertto soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Avertto

Avertto is a medical device startup based in Israel that aims to revolutionize stroke prevention and treatment. The company's slogan, "Monitor. Detect. Alert," reflects its core mission. Avertto's flagship product is the first insertable medical device with AI capabilities that provides alerts for impending strokes. This is particularly significant given that stroke is a $1T problem and the leading cause of disability, with 85% of cases remaining untreated. Avertto's subcutaneous telemonitoring medical device utilizes AI and signal analysis to detect changes in carotid pulse waves and send timely alerts to healthcare providers, enabling early treatment and potentially preventing neurological damage. Avertto's hybrid go-to-market strategy involves in-patient clinical studies with a rigorous domesticated regulatory pathway, positioning the company for large-scale adoption in the home market. The potential of the home market for Avertto is substantial, with 120M patients yearly at risk of stroke, amounting to a total addressable market of $500K. The company's seasoned and diverse team of entrepreneurs has successfully raised $2M and is conducting blinded clinical studies across 7 clinical sites in Israel, Spain, and the USA to prove the value of Avertto's innovative solution. The most recent investment in Avertto was a $75.00K Pre Seed Round led by the European Innovation Council, demonstrating increasing interest in the company's potential to disrupt the healthcare industry and change the standard of care for stroke prevention and treatment. With its promising technology, strategic approach, and experienced team, Avertto is poised to make a meaningful impact in improving and extending lives.

Business keywords: medical device, stroke prevention, telemonitoring, clinical studies, regulatory approval, entrepreneurship, investment, proof of concept, disability prevention

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Pre Seed Round $75.00K 1
European Innovation Council
European Innovation Council
01 Jul 2022

Avertto Alternatives & Competitors

View All Alternatives
Avertto vs
Oxford Endovascular Ltd.
Oxford Endovascular Ltd. United Kingdom

Saving Lives Treating Brain Aneurysms - 'Origami Engineering' for the Brain

Series A
6 employees
Biotechnology, Health Care
Avertto vs
Intrinsic Therapeutics, Inc
Intrinsic Therapeutics, Inc United States

Manufacturer of Barricaid® Designed to prevent reherniation.

Venture round
75 employees
Health Care, Manufacturing
Avertto vs
QREC Clinical Research LLP
QREC Clinical Research LLP India

CRO serving complete Healthcare Industry for Clinical Trials (Phase 3 & 4), Medical Writing, CDM, St...

28 employees
Health Care
View all alternatives

FAQ About Avertto

Monitor. Detect. Alert
Avertto was founded in 2019.
Avertto is headquartered in Israel.
Avertto operates in Health Care. Its work centres on medical device, stroke prevention, telemonitoring and clinical studies.
Avertto has approximately 10 employees.
Avertto has completed 1 funding round, raising a total of $75.00K. The latest funding stage is Pre-Seed.
Top alternatives and competitors to Avertto include Oxford Endovascular Ltd., Intrinsic Therapeutics, Inc, QREC Clinical Research LLP, Transverse Medical Inc, Protembis GmbH. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Avertto and Oxford Endovascular Ltd. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Avertto, https://bouncewatch.com/company/avertto, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes